Literature DB >> 24197985

Comparative effectiveness of radiofrequency ablation with or without transarterial chemoembolization for hepatocellular carcinoma.

Qing-Feng Kong1, Jun-Bo Jiao, Qian-Qian Chen, Long Li, Dong-Guang Wang, Bin Lv.   

Abstract

The aim of this study is to compare the overall survival in patients with hepatocellular carcinoma (HCC) treated with radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) versus RFA alone. All eligible studies were collected from the PubMed, the Cochrane Library, and the Embase electronic databases. The outcomes were overall survival rates. We used odds ratios to assess the strength of the association, and 95% confidence intervals give a sense of the precision of the estimate. Statistical analyses were performed by Review Manager 5.0 and Stata 11.0. A total of 19 available studies were considered in the present meta-analysis. When all groups were pooled, meta-analysis showed that RFA plus TACE significantly improved the survival rates of patients with HCC at 1, 3, and 5 years compared with RFA alone. The combination of RFA with TACE has advantages in improving overall survival rate, and provides better prognosis for HCC patients.

Entities:  

Mesh:

Year:  2013        PMID: 24197985     DOI: 10.1007/s13277-013-1349-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  31 in total

1.  Intraoperative radiofrequency thermal ablation combined with portal vein infusion chemotherapy and transarterial chemoembolization for unresectable HCC.

Authors:  Shi-Qiang Shen; Jin-Jian Xiang; Cheng-Long Xiong; Shan-Min Wu; Shan-Shan Zhu
Journal:  Hepatogastroenterology       Date:  2005 Sep-Oct

2.  [Quality of life of primary hepatocellular carcinoma patients after radiofrequency ablation].

Authors:  Yan-Bin Wang; Min-Hua Chen; Kun Yan; Wei Yang; Ying Dai; Shan-Shan Yin
Journal:  Ai Zheng       Date:  2005-07

3.  A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

Authors:  Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Ryosuke Tateishi; Tomonori Fujishima; Takashi Ishikawa; Yukihiro Koike; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

4.  Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm.

Authors:  Shi-Ming Lin; Chun-Jung Lin; Chen-Chun Lin; Chao-Wei Hsu; Yi-Cheng Chen
Journal:  Gastroenterology       Date:  2004-12       Impact factor: 22.682

5.  [Radiofrequency ablation with or without transcather arterial chemoembolization for management of hepatocellular carcinoma].

Authors:  Zheng-ran Li; Zhuang Kang; Jie-sheng Qian; Kang-shun Zhu; Zai-bo Jiang; Ming-sheng Huang; Shou-hai Guan; Hong Shan
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2007-11

6.  Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial.

Authors:  Bao-Quan Cheng; Chong-Qi Jia; Chun-Tao Liu; Wei Fan; Qing-Liang Wang; Zong-Li Zhang; Cui-Hua Yi
Journal:  JAMA       Date:  2008-04-09       Impact factor: 56.272

7.  Efficacy of mesenchymal stem cells in suppression of hepatocarcinorigenesis in rats: possible role of Wnt signaling.

Authors:  Mohamed T Abdel aziz; Mohamed F El Asmar; Hazem M Atta; Soheir Mahfouz; Hanan H Fouad; Nagwa K Roshdy; Laila A Rashed; Dina Sabry; Amira A Hassouna; Fatma M Taha
Journal:  J Exp Clin Cancer Res       Date:  2011-05-05

8.  More expressions of BDNF and TrkB in multiple hepatocellular carcinoma and anti-BDNF or K252a induced apoptosis, supressed invasion of HepG2 and HCCLM3 cells.

Authors:  Dawei Guo; Xuezhong Hou; Hongbin Zhang; Wenyu Sun; Lei Zhu; Jian Liang; Xiaofeng Jiang
Journal:  J Exp Clin Cancer Res       Date:  2011-10-14

Review 9.  Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis.

Authors:  Hongtuan Zhang; Yong Xu; Zhihong Zhang; Ranlu Liu; Baojie Ma
Journal:  BMC Immunol       Date:  2012-03-21       Impact factor: 3.615

10.  Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer.

Authors:  Farbod Shojaei; Nathan Scott; Xiaolin Kang; Patrick B Lappin; Amanda A Fitzgerald; Shannon Karlicek; Brett H Simmons; Aidong Wu; Joseph H Lee; Simon Bergqvist; Eugenia Kraynov
Journal:  J Exp Clin Cancer Res       Date:  2012-03-23
View more
  5 in total

1.  Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis.

Authors:  Zhenyin Liu; Fei Gao; Guang Yang; Sristi Singh; Mingjian Lu; Tao Zhang; Zhihui Zhong; Fujun Zhang; Rijie Tang
Journal:  Tumour Biol       Date:  2014-04-29

2.  Efficacy and Safety of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Hepatocellular Carcinomas Compared with Radiofrequency Ablation Alone: A Time-to-Event Meta-Analysis.

Authors:  Xin Wang; Yanan Hu; Mudan Ren; Xinlan Lu; Guifang Lu; Shuixiang He
Journal:  Korean J Radiol       Date:  2016-01-06       Impact factor: 3.500

3.  Management of hepatocellular carcinoma: an overview of major findings from meta-analyses.

Authors:  Xingshun Qi; Yan Zhao; Hongyu Li; Xiaozhong Guo; Guohong Han
Journal:  Oncotarget       Date:  2016-06-07

Review 4.  Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy.

Authors:  Ji Hye Jang; Jin-Woo Lee; Ji Taek Hong; Young-Joo Jin
Journal:  J Hepatocell Carcinoma       Date:  2015-09-02

5.  Surrogate endpoint for overall survival in assessment of adjuvant therapies after curative treatment for hepatocellular carcinoma: a re-analysis of meta-analyses of individual patients' data.

Authors:  Hong-Bo Huan; Li-Li Wu; Wan-Yee Lau; Xu-Dong Wen; Liang Zhang; Da-Peng Yang; Xi-Shu Wang; Ping Bie; Feng Xia
Journal:  Oncotarget       Date:  2017-06-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.